Live feed07:00:00·401dPRReleasevia QuantisnowZai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung CancerByQuantisnow·Wall Street's wire, on your screen.ZLAB· Zai Lab LimitedHealth Care
